Glioblastoma Multiforme
Conditions
Keywords
Glioblastoma multiforme, Immunotherapy, Bevacizumab/Irinotecan, ALECSAT, recurrent
Brief summary
The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in patients with relapse of GlioBlastoma Multiforme (GBM) after first line treatments (followed by reoperation if possible). The efficacy and safety of ALECSAT treatment is, compared to standard Bevacizumab/Irinotecan second line treatments for these patients.
Detailed description
This study is an open-label, randomized, prospective, parallel group phase II study with ALECSAT compared to Bevacizumab/Irinotecan in patients with verified relapsed glioblastoma multiforme after or during treatment with recognised first-line treatment. After 62 PFS events have been recorded, an interim analysis will be conducted under the auspices of the Data Monitoring Committee. The patients in the two treatment groups will be followed for up to 62 weeks by planned study visits. Patients with, at least, stable disease will continue the allocated treatment after the study period as judged by the Investigator. Patients allocated to the Bevacizumab/Irinotecan (control group) will receive their treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle of Bevacizumab/Irinotecan consist of 2 dosing days; day 1 and day 15 in the cycle.
Interventions
BIOLOGICALALECSAT
The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
Sponsors
CytoVac A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed GBM tumour with recurrence during or after completing the recognized first-line treatments, tumor recurrence, documented by MRI, * Minimum age of 18 years old, * Capable of understanding the information and giving informed consent * Minimum height of 155 cm * Expected survival time (life expectancy) of over 3 months * Adequate performance status equal or below 2 * Clinically normal Erythrocyte Volume Fraction (EVF) * Women in fertile conditions can only be included with a negative pregnancy test at screening and must use appropriate contraceptives during the study
Exclusion criteria
* Positive tests for HIV-1/2; HBsAg, hemoglobin C, hepatitis C virus, or being positive in a Treponema Pallidum test (syphilis) * Patients who may have been exposed to West Nile virus, or Dengue virus or human T-cell lymphotrophic virus (HTLV-1) virus should be excluded, unless the patient has been tested negative * Concurrent illness, e.g. uncontrolled epilepsy, cardiovascular-, cerebrovascular-, and/or respiratory disease which can worsen or cause complications in connection with blood donation * Clinically significant autoimmune disorders or conditions of immune suppression * Hemoglobin count ≤ 7.5mmol/l (men & women) * Lymphocyte-numbers below 0.5 x 109/l * Body weight below 40 kg (men) and 50 kg (women) * Clinically abnormal ECG as judged by the Investigator * Pregnant or breast feeding women * Inclusion in other clinical studies 4 weeks prior to inclusion in the study * Any medical condition that will render participation in the study risky or, according to the Investigator will make the assessment of the study endpoints difficult * Treatment with any immunotherapy, cytotoxic therapy or, biologic therapy 4 weeks prior to enrolment in this study * Patients that either may be put at risk due to the blood donation or where it is not expected that an ALECSAT product of good quality can be produced, as judged by the Investigator * Patients with uncontrolled serious bacterial, viral, fungal or parasitic infection * Blood transfusions within 48 hours prior to donation of blood for ALECSAT production * Known or suspected intolerance to Avastin, Irinotecan or any of the excipients as well as intolerance to recombinant humanized antibodies Performance status ≥ 3
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | During the study period up to 62 weeks | To compare progression-free survival (PFS) in patients with relapsed GBM when the patients are either treated with ALECSAT immunotherapy or standard praxis therapy with Bevacizumab/Irinotecan. Progression of disease is defined according to the response evaluation criteria for solid tumours (RANO) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | During the study period up to 62 weeks | To evaluate the overall survival (OS) during the study period in patients treated with ALECSAT compared to patients treated with Bevacizumab/Irinotecan by Kaplan-Meier methodology |
| Time to progression (TTP) | During the study period up to 62 weeks | To evaluate time to progression in the two treatment groups To compare PFS in the two treatment groups by Kaplan-Meier methodology upon study completion To compare PFS in a landmark analysis in the two treatment groups after a duration of 6 and 12 months after initiation of treatment |
| Quality of Life by European Organization for Research and Treatment of Cancer (EORTC) questionnaire | During the study period up to 62 weeks | To investigate QoL and performance status during the study period for patients treated with ALECSAT compared to patients treated with Avastin/Irinotecan |
| Overall Response Rate (ORR) | During the study period up to 62 weeks | To compare Objective Response Rate (ORR) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety & tolerability | During the study period up to 62 weeks | Comparison of type and frequency of AEs; changes in biochemical parameters of clinical relevance; in hematology parameters of clinical relevance; in vital signs and change in electrocardiogram (ECG). Evaluation of medical events of special interest. |
Countries
Denmark
Outcome results
None listed